Clinical Trial Update: Pharmacodynamics, Pharmacokinetics, Safety and Tolerability of SHR3824 in Type 2 Diabetes Mellitus Patients [Phase 1]

View source ↗

Summary

Phase 1 trial evaluating pharmacodynamics, pharmacokinetics, safety and tolerability of SHR3824 in patients with Type 2 diabetes mellitus.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Type 2 Diabetes Mellitus

Drugs mentioned

• SHR3824

Snippet

Sponsor: Jiangsu HengRui Medicine Co., Ltd. | Conditions: Type 2 Diabetes Mellitus | Phase 1 | Status: COMPLETED